IntelliCell BioSciences Has Received Its Hong Kong Patent Application Notice for ULTRASONIC CAVITATION
April 02 2014 - 11:57AM
Marketwired
IntelliCell BioSciences Has Received Its Hong Kong Patent
Application Notice for ULTRASONIC CAVITATION
NEW YORK, NY--(Marketwired - Apr 2, 2014) - IntelliCell
BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a
regenerative medicine company utilizing adult autologous vascular
fraction cells (SVFCs) derived from the blood vessels found in
adipose tissue, has received notice of publication for its
technology patent in Hong Kong for ULTRASONIC CAVITATION DERIVED
STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED
THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USE THEREOF. HK Patent
Application No 13113908.9
IntelliCell's Chief Executive Officer, Dr. Victor, remarked,
"This is wonderful news in that we are expanding our international
patent portfolio to further protect our patent around the
world. And I believe that we are now in the phase of our
international patent process to reach out and seek international
partners to whom we would license our technology and cellular labs
and start generating international revenues."
About IntelliCell Biosciences IntelliCell is a pioneering
regenerative medicine company focused on the expanding regenerative
medical markets using adult autologous stromal vascular fraction
cells (SVFCs) derived from the blood vessels in the adult adipose
tissue. IntelliCell BioSciences has developed its own patented
technology and protocol to separate adult autologous vascular cells
from adipose tissue without the use of enzymes. IntelliCell will
also be seeking to develop technology-licensing agreements with
technology developers, universities, and international business
entities.
Forward-Looking Statements Certain statements set forth in this
press release constitute "forward-looking statements."
Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future
results, performance or achievements, and may contain the words
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning," "expect," "believe," "will likely," "will reach," "will
change," "will soon," "should," "could," "would," "may," "can" or
words or expressions of similar meaning. Such statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause the company's actual results and
financial position to differ materially from those included within
the forward-looking statements. Forward-looking statements involve
risks and uncertainties, including those relating to the Company's
ability to grow its business. Actual results may differ materially
from the results predicted and reported results should not be
considered as an indication of future performance. The potential
risks and uncertainties include, among others, the Company's
limited operating history, the limited financial resources,
domestic or global economic conditions, activities of competitors
and the presence of new or additional competition, and changes in
Federal or State laws. More information about the potential factors
that could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact: IntelliCell BioSciences, Inc. Investor Relations Anna
Rhodes Email Contact (646) 576-8308